Analyst Kostas Biliouris from BMO Capital maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) and keeping the price target at $300.00.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Kostas Biliouris has given his Buy rating due to a combination of factors influencing Alnylam Pharma’s market position and future prospects. One of the key reasons is the strong uptake of Attruby, which has exceeded expectations and indicates a positive trend for Alnylam’s product launches, particularly with the anticipated success of Amvuttra. The ATTR-CM market is expanding, with significant growth in new patient starts, and Alnylam is well-positioned to capture a substantial share of this market with its innovative treatments.
Additionally, Alnylam’s robust and diverse RNAi portfolio, which includes several FDA/EMA-approved drugs, supports its potential for sustained growth. The company’s strategic focus on addressing unmet medical needs and its ability to capture market share in rare disease segments further reinforce the Buy rating. The early impact of Amvuttra’s launch on Attruby’s uptake and the potential for increased diagnosis rates are expected to drive continued sales growth, making Alnylam an attractive investment opportunity.
In another report released yesterday, RBC Capital also maintained a Buy rating on the stock with a $330.00 price target.